Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada
Conditions
Duchenne Muscular Dystrophy · Becker Muscular Dystrophy · Dystrophinopathy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Royal Children's Hospital, Parkville, Melbourne, Australia
Institute For Neuromuscular Research, The Children's Hospital at Westmead, Westmead, Australia
University Hospital KU Leuven, Leuven, Belgium
Alberta Children's Hospital, Calgary, Alberta, Canada
British Columbia Children's Hospital, Vancouver, British Columbia, Canada
Children's Hospital of Western Ontario, London, Ontario, Canada
Hôpital d'Enfants CHU Timone, Marseille, France
Laboratoire d'Exploration Fonctionnelles, Nantes, France
Groupe Hospitalier La Pitie-Salpetriere, Paris, France
University of Essen - Clinic for Children, Essen, Germany
University Hospital, Freiburg im Breisgau, Germany
Hadassah Medical Center, Hebrew University Hospital, Jerusalem, Israel
Ospedale Maggiore Policlinico in Milan, Milan, Italy
Ospedale Pediatrico Bambino Gesu, Rome, Italy
U.O. Complessa di Neuropsichiatria Infantile, Rome, Italy
Hospital Sant Joan de déu, Barcelona, Spain
Hospital Universitari La Fe, Valencia, Spain
Queen Silvia Children's Hospital, Gothenburg, Sweden
Astrid Lindgren Pediatric Hospital, Stockholm, Sweden
Great Ormond Street Hospital, London, United Kingdom
University of Newcastle Institute of Human Genetics, Newcastle upon Tyne, United Kingdom
Study leads
Edward O'Mara, MD
Study Director
PTC Therapeutics